Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients

Giuseppe Derosa, Arrigo F G Cicero, Anna Carbone, Fabrizio Querci, Elena Fogari, Angela D'Angelo, Pamela Maffioli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.

Original languageEnglish
Pages (from-to)154-162
Number of pages9
JournalInflammation
Volume37
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Amlodipine
Blood Pressure
Inflammation
Calcium
Fasting
Chemokine CCL2
Angiotensin Receptor Antagonists
Adiponectin
C-Reactive Protein
Insulin Resistance
Insulin
Macrophage Migration-Inhibitory Factors
Lipids
Therapeutics
Calcium Channel Blockers
Double-Blind Method
Homeostasis
Body Weight
olmesartan

Keywords

  • adiponectin
  • amlodipine
  • high sensitivity C-reactive protein
  • monocyte chemoattractant protein-1
  • olmesartan

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. / Derosa, Giuseppe; Cicero, Arrigo F G; Carbone, Anna; Querci, Fabrizio; Fogari, Elena; D'Angelo, Angela; Maffioli, Pamela.

In: Inflammation, Vol. 37, No. 1, 02.2014, p. 154-162.

Research output: Contribution to journalArticle

@article{1305d53f4f484e128104b0d51f55b22b,
title = "Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients",
abstract = "This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.",
keywords = "adiponectin, amlodipine, high sensitivity C-reactive protein, monocyte chemoattractant protein-1, olmesartan",
author = "Giuseppe Derosa and Cicero, {Arrigo F G} and Anna Carbone and Fabrizio Querci and Elena Fogari and Angela D'Angelo and Pamela Maffioli",
year = "2014",
month = "2",
doi = "10.1007/s10753-013-9724-x",
language = "English",
volume = "37",
pages = "154--162",
journal = "Inflammation",
issn = "0360-3997",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients

AU - Derosa, Giuseppe

AU - Cicero, Arrigo F G

AU - Carbone, Anna

AU - Querci, Fabrizio

AU - Fogari, Elena

AU - D'Angelo, Angela

AU - Maffioli, Pamela

PY - 2014/2

Y1 - 2014/2

N2 - This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.

AB - This study aims to evaluate the effects of an angiotensin receptor blocker (ARB)/calcium channel blocker combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation markers. We randomized 276 hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We evaluated the following: body weight, systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1β (MIP-1β). Olmesartan/amlodipine combination better reduced blood pressure, FPI, homeostasis model assessment index, and increased M value and ADN compared to olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly decreased Hs-CRP, MCP-1, and MIP-1β. In this multicenter, randomized, double-blind, clinical study, ARB/calcium antagonist combination resulted to be more effective than single monotherapies in reducing blood pressure, in improving insulin sensitivity, and in reducing inflammation parameters in patients with stage I essential hypertension.

KW - adiponectin

KW - amlodipine

KW - high sensitivity C-reactive protein

KW - monocyte chemoattractant protein-1

KW - olmesartan

UR - http://www.scopus.com/inward/record.url?scp=84900351465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900351465&partnerID=8YFLogxK

U2 - 10.1007/s10753-013-9724-x

DO - 10.1007/s10753-013-9724-x

M3 - Article

VL - 37

SP - 154

EP - 162

JO - Inflammation

JF - Inflammation

SN - 0360-3997

IS - 1

ER -